logo

SALIX PHAR(NSDQ:SLXP)
Salix Pharmaceuticals, Ltd. objective is to be a market-driven specialtypharmaceutical company focussed on the needs of physicians specializing ingastroenterology. The company intends to establish a small direct sales force to promote its products to this specialist audience. The company''s strategy is to identify and acquire products that have near-term commercial potential and apply its regulatory and product development expertise to commercialize these products. The company selects products that it believes serve a gastrointestinal disease.
# Employees: 280
Address: 1700 Perimeter Park Drive,Morrisville,NC,USA
Phone: 919 862-1000
Fax: 919 862-1095
Website: www.salix.com
Email: investor.relations@salix.com
Sector: Medical
Industry: MED-DRUGS
Executive Officers
John F. Chappell (Chmn.)
Carolyn J. Logan (Presi.; C.E.O.; Dir.)
Adam C. Derbyshire (Sr. V.P. Fin & Admn.; C.F.O.)
William P. Forbes (V.P.; Research & Devlpt.; Chief Devlpt. Off.)
Richard A. Franco (Dir.,)
Dividend
Ex-Dividend Date: N/A
Annual Dividend: N/A
Current Dividend Yield: N/A
Dividend Paid (3 months): N/A
Indicated Dividend: N/A
Earnings
Last Earnings Date: 9/30/2009
Next Earnings Date(Expected): 3/9/2010
Mean EPS (Next Qtr): ($0.14)
Mean EPS (Year): ($0.89)
Mean Estimate(Long Term): $43.50
P/E Ratio(Based on EPS estimate): -0.010
Number of Estimates: 8
Shares Performance
Period SLXP Compare to S&P
YTD 158.10 % 113.59 %
4 Weeks 23.93 % 17.65 %
12 Weeks 79.17 % 66.84 %
Shares Information
Analyst Coverage: Y
Avg Volume: 819892
Shares Outstanding: 48M
Market Cap: $1.11B
52 Week High: $24.08
52 Week Low: $6.15
P/E Ratio: -0.010
PEG Ratio: -0.010
Split: On 7/13/2004 SLXP split by factor of 1.500
Earnings Performance
EPS Growth in Last Quarter: 53.12 %
EPS Growth in Last Year: -36.36 %
Sales Growth in Last Quarter: 25.70 %
Sales Growth in Last Quarter: 53.15 %
Financials
Qtr Book Value: $4.33
Cash Flow/Share: ($0.01)
Change in Payout Ratio: -0.010
Price/Sales: 4.980
Fundamental data is provided by Zacks Investment Research, market data is provided by AlphaTrade. , and Commentary and Press Releases provided by Quotemedia